Literature DB >> 11134129

A novel missense mutation of mineralocorticoid receptor gene in one Japanese family with a renal form of pseudohypoaldosteronism type 1.

T Tajima1, H Kitagawa, S Yokoya, K Tachibana, M Adachi, J Nakae, S Suwa, S Katoh, K Fujieda.   

Abstract

Pseudohypoaldosteronism type 1 (PHA1) is a rare condition characterized by neonatal salt loss with dehydration, hypotension, hyperkalemia, and metabolic acidosis, despite elevated plasma aldosterone levels and PRA. Two modes of inheritance of PHA1 have been described: an autosomal dominant form and an autosomal recessive form. An autosomal recessive form manifests severe life-long salt wasting resulting from multiple mineralocorticoid target tissue such as sweat, salivary glands, the colonic epithelium, and lung. Contrary, an autosomal dominant PHA1 manifests milder salt wasting that gradually improves with advancing age. Recently, in one sporadic and four dominant cases, four different mutations including two frame shift mutations, two premature termination codons, and one splice site mutation in the mineralocorticoid receptor (MR) gene were identified. We studied the molecular mechanisms of one Japanese family with a renal form of PHA1. PCR and direct sequencing of the MR gene identified a heterozygous point mutation changing codon 924 Leu (CTG) to CCG (Pro) (L924P) in all affected members. COS-1 cells were transfected with expression vectors for either wild type or the mutant MR-L924P receptors, together with the reporter plasmid (glucocorticoid response element tk-CAT). Aldosterone increased CAT activity in cells expressing wild-type receptor, but had no effect in cells expressing the mutant receptors. These results suggest that mineralocorticoid resistance in this family is due to a missense mutation in the MR gene. To our knowledge, this is the first case of the missense mutation of the MR gene in renal PHA1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11134129     DOI: 10.1210/jcem.85.12.7078

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Increased Na reabsorption via the Na-Cl cotransporter in autosomal recessive pseudohypoaldosteronism.

Authors:  Masanori Adachi; Yumi Asakura; Koji Muroya; Toshihiro Tajima; Kenji Fujieda; Emiko Kuribayashi; Shunya Uchida
Journal:  Clin Exp Nephrol       Date:  2010-04-08       Impact factor: 2.801

2.  A case of pseudohypoaldosteronism type 1 with a mutation in the mineralocorticoid receptor gene.

Authors:  Se Eun Lee; Yun Hye Jung; Kyoung Hee Han; Hyun Kyung Lee; Hee Gyung Kang; Il Soo Ha; Yong Choi; Hae Il Cheong
Journal:  Korean J Pediatr       Date:  2011-02-28

3.  A novel mutation in the human mineralocorticoid receptor gene in a Japanese family with autosomal-dominant pseudohypoaldosteronism type 1.

Authors:  Yoshimi Nishizaki; Makoto Hiura; Hidetoshi Sato; Yohei Ogawa; Akihiko Saitoh; Keisuke Nagasaki
Journal:  Clin Pediatr Endocrinol       Date:  2016-10-18

4.  Clinical features and molecular basis of pseudohypoaldosteronism type 1.

Authors:  Toshihiro Tajima; Shuntaro Morikawa; Akie Nakamura
Journal:  Clin Pediatr Endocrinol       Date:  2017-07-27

5.  Autosomal dominant pseudohypoaldosteronism type 1 with a novel splice site mutation in MR gene.

Authors:  Kyoko Kanda; Kandai Nozu; Naoki Yokoyama; Ichiro Morioka; Akihiro Miwa; Yuya Hashimura; Hiroshi Kaito; Kazumoto Iijima; Masafumi Matsuo
Journal:  BMC Nephrol       Date:  2009-11-14       Impact factor: 2.388

6.  Two Japanese patients with the renal form of pseudohypoaldosteronism type 1 caused by mutations of NR3C2.

Authors:  Shuntaro Morikawa; Nagisa Komatsu; Sonoko Sakata; Akari Nakamura-Utsunomiya; Satoshi Okada; Toshihiro Tajima
Journal:  Clin Pediatr Endocrinol       Date:  2015-07-18

Review 7.  One-month-old girl presenting with pseudohypoaldosteronism leading to the diagnosis of CDK13-related disorder: a case report and review of the literature.

Authors:  Renata Yakubov; Asaly Ayman; Adi Klein Kremer; Machiel van den Akker
Journal:  J Med Case Rep       Date:  2019-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.